Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Nov 11:12:776871.
doi: 10.3389/fendo.2021.776871. eCollection 2021.

Editorial: Proglucagon-Derived Peptides

Peter R Flatt  1 , Filip K Knop  2   3   4   5 , Andrei I Tarasov  1
Affiliations
Editorial

Editorial: Proglucagon-Derived Peptides

Peter R Flatt et al. Front Endocrinol (Lausanne). .
No abstract available

Keywords: L-cell; alpha-cell; diabetes; intestinal function; metabolism; obesity; proglucagon-derived peptides; therapeutics.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
(A) Structure of proglucagon, post-translational processing and the major targets of constituent bioactive peptides: glucagon, GLP-1, GLP-2, oxyntomodulin, glicentin and glicentin-related pancreatic polypeptide. (B) Numbers of peer-reviewed publications on proglucagon-derived peptides showing particularly strong surge of research on GLP-1. (C) Publication count by geographical location divided by population of each country (source: PubMed).
Figure 2
Figure 2
Contributors to some of the early milestones on proglucagon-derived peptides. Top panel (from left): Professor Steve Bloom, Professor J. Michael Conlon, Professor Julia Polak, Professor Flemming Stadil, Professor Kazuhiko Tatemoto and Professor Keith Buchanan pictured at the Annual Meeting of Bayliss & Starling Society, held in Belfast 1987 (reproduced with permission from Belfast Telegraph). Bottom panels (from left): Professor Bo Hellman (1996), Professor Vincent Marks (1989) and Professor Jens Holst (2020). BH by Lennart Nilsson, VM by PRF and JJH by Ricky Molloy. All photographs reproduced with permission.
See this image and copyright information in PMC

Comment on

  • Editorial on the Research Topic Proglucagon-Derived Peptides

Similar articles

See all similar articles

References

    1. Drucker DJ, Habener JF, Holst JJ. Discovery, Characterization, and Clinical Development of the Glucagon-Like Peptides. J Clin Invest (2017) 127(12):4217–27. doi: 10.1172/JCI97233 - DOI - PMC - PubMed
    1. Müller TD, Finan B, Clemmensen C, DiMarchi RD, Tschöp MH. The New Biology and Pharmacology of Glucagon. Physiol Rev (2017) 97(2):721–66. doi: 10.1152/physrev.00025.2016 - DOI - PubMed
    1. Drucker DJ. The Discovery of GLP-2 and Development of Teduglutide for Short Bowel Syndrome. ACS Pharmacol Transl Sci (2019) 2(2):134–42. doi: 10.1021/acsptsci.9b00016 - DOI - PMC - PubMed
    1. Müller TD, Finan B, Bloom SR, D'Alessio D, Drucker DJ, Flatt PR, et al. . Glucagon-Like Peptide 1 (GLP-1). Mol Metab (2019) 30:72–130. doi: 10.1016/j.molmet.2019.09.010 - DOI - PMC - PubMed
    1. Marks V. Rebirth of the Incretin Concept: Its Conception and Early Development. Peptides (2018) 100:3–8. doi: 10.1016/j.peptides.2017.08.002 - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources